If we compare figures with ACL's announcement in Feb,
IMS total market $ share in Feb = 18%
IMS total market $ share in May = 22% (ie sales increase of at least 20% (4/18) not allowing for increase in total market)
Retail $ market share in Feb = 30%
Retail $ market share in May = "nearly about 50%"
We don't know how much prescription volume has increased.
There seems to be a conflict between the retail % of total market from DRR compared to what was indicated by PS 3 mths ago, but that might be lost in translation.
I'd imagine if sales were $1.4M/week in Feb, current figure would be $1.7-$2.0M/week, which is probably up around $25-30M annualised for ACL (assuming profit = 60% of sales)
And I take it that there are now no capacity constraints.
It all sounds positive.
- Forums
- ASX - By Stock
- TSN
- sp and cash
sp and cash, page-38
-
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add TSN (ASX) to my watchlist
|
|||||
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.409M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
TSN (ASX) Chart |
Day chart unavailable
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, MD & CEO
Anthony Noble
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online